Paul William Craven, M.D. Ophthalmology Medicare: Accepting Medicare Assignments Practice Location: 4859 Dover Center Rd, #7, North Olmsted, OH 44070 Phone: 440-734-4090 Fax: 440-734-2231 |
News Archive
Commenting on Edward Boyden's article, Ben Barres, Head of the Neuronal & Glial Cell Biology Section of Faculty of 1000 and Professor at Stanford University School of Medicine said: "There will probably be a Nobel prize for optogenetics someday as it has revolutionized our attempts to understand how the brain works. This article provides a fascinating insight into the birth of optogenetics and the roles of the major players."
Euthymics Bioscience, Inc. today will present Phase II clinical data demonstrating that its lead product candidate EB-1010, a next-generation antidepressant, is effective for treating major depressive disorder (MDD) based on multiple standard measures of outcome for depression. EB-1010 also improved measures of anhedonia, a hallmark symptom of MDD, which is characterized by the inability to experience pleasure.
Researchers estimate that up to $101 billion in health care spending is wasted each year due to over-treatment or the delivery of "low-value care." Low-value care includes a wide array of tests and treatments that are medically unnecessary and for which the potential for harm outweigh the potential for benefit. While researchers have charted the ongoing use of low-value care on national and regional levels, little research exists on how health systems across the country use low-value care and how they compare to each other.
Eisai announced today that the European Medicines Agency's Committee for Medicinal Products for Human Use (CHMP) has issued a positive opinion for the use of Fycompa (perampanel) as an adjunctive treatment of partial-onset seizures, with or without secondarily generalised seizures, in patients with epilepsy aged 12 years and older.
› Verified 3 days ago